LIFE SCIENCE PRODUCTS MARKET ANALYSIS

Life Science Products Market, By Product (Recombinant Proteins (Immune Checkpoint Regulators, Chemokines, Growth Factors, Cytokines, Colony Stimulating Factors, Hormones, Enzymes & Inhibitors, Others), Cell Lines (Immunotherapy Cell Lines, Ion Channel Cell Lines, GPCR Cell Lines, Cell Signaling Pathway Cell Lines, Gene Knockout Cell Lines, Cancer Cell Lines, Others), Antibodies (Immune Checkpoint Antibodies, Epitope Tag Antibodies, Isotype Control Antibodies (Research Use, In-vivo Grade), Primary Antibodies (Research Use, In-vivo Grade), Assay Antibodies (includes secondary antibodies), Others(Viable Tumor Samples, Tumor Tissue Microarrays)), By Application (Drug Discovery & Development, Basic Research, Toxicity Screening, Biopharmaceutical Production, Drug Screening, Tissue Engineering, Forensic Testing), By End User (Biopharmaceutical Companies, Contract Research Organizations (CROs), Academic & Research Institutes, Forensic Science Laboratories, Food & Beverage Companies, Diagnostic Centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Jun 2023
Code : CMI3652
Pages :180
Formats :
Excel and PDF
Industry : Biotechnology

Market News

Global Life Science Products Market: Key Developments

On February 15, 2023, Lantern Pharma Inc., a clinical-stage biopharmaceutical company using its proprietary RADR artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced expansions and updates to RADR’s product roadmap, which will further enhance its oncology drug discovery capabilities. These RADR advancements will focus on additional innovative AI and ML approaches to develop Antibody Drug Conjugates (ADCs), which are highly specific cancer-targeted antibodies linked to potent anti-tumor small molecules and designed for the treatment of cancer.

In May 2022, Novotech, a clinical CRO, announced the acquisition of NCGS, a U.S.-based CRO, as part of a service expansion program for its global base of clients.

In August 2022, Amgen Inc, a pharmaceutical company, announced the acquisition of ChemoCentryx, Inc., a pharmaceutical company, to treat autoimmune diseases, inflammatory disorders, and cancer.

In September 2021, Aviva Systems Biology, one of the companies engaged in manufacturing and developing antibodies, immunoassay kits, and recombinant proteins for life science research, launched its new protein-on-demand, semi-custom recombinant protein portfolio for life scientists conducting basic research and preclinical studies